A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

Also called NCT01672762

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01672762
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01672762. Allocation not applicable; no masking; primary purpose treatment. Start 2012-05-25 (actual); primary completion 2013-04-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ipragliflozin
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01672762
Content hash
56105001df0aa9f28b9523d5757bd923ffc68ea89b92f8318f89d8e99371a715